These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 29411746)

  • 1. [Cerebroprotective activity of metformin, gosogliptin, citicoline and a novel GPR119 agonist in cerebral ischemia under experimental diabetes mellitus].
    Tyurenkov IN; Kurkin DV; Bakulin DA; Volotova EV; Chafeev MA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(12. Vyp. 2):53-59. PubMed ID: 29411746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZB-16, a Novel GPR119 Agonist, Relieves the Severity of Streptozotocin-Nicotinamide-Induced Diabetes in Rats.
    Tyurenkov IN; Kurkin DV; Bakulin DA; Volotova EV; Chafeev MA; Smirnov AV; Morkovin EI
    Front Endocrinol (Lausanne); 2017; 8():152. PubMed ID: 28736546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of co-administration of metformin and evogliptin on cerebral infarct volume in the diabetic rat.
    Lee SJ; Yoon BS; Hong JM; Joe EH; Lee JS
    Exp Neurol; 2022 Feb; 348():113922. PubMed ID: 34780772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
    Osonoi T; Saito M; Hariya N; Goto M; Mochizuki K
    Peptides; 2016 Dec; 86():118-125. PubMed ID: 27780736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
    Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
    Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y; Hong T
    Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effect of glucagon-like peptide-1 receptor agonist is independent of glycaemia normalization in type two diabetic rats.
    Filchenko I; Simanenkova A; Chefu S; Kolpakova M; Vlasov T
    Diab Vasc Dis Res; 2018 Nov; 15(6):567-570. PubMed ID: 30024276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
    Wu T; Little TJ; Bound MJ; Borg M; Zhang X; Deacon CF; Horowitz M; Jones KL; Rayner CK
    Diabetes Care; 2016 Apr; 39(4):511-7. PubMed ID: 26786576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemistry and Hypoglycemic Activity of GPR119 Agonist ZB-16.
    Tyurenkov IN; Kurkin DV; Bakulin DA; Volotova EV; Morkovin EI; Chafeev MA; Karapetian RN
    Front Endocrinol (Lausanne); 2018; 9():543. PubMed ID: 30283402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?
    Wu T; Thazhath SS; Bound MJ; Jones KL; Horowitz M; Rayner CK
    Diabetes Res Clin Pract; 2014 Oct; 106(1):e3-6. PubMed ID: 25172519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport.
    Hurtado O; Moro MA; Cárdenas A; Sánchez V; Fernández-Tomé P; Leza JC; Lorenzo P; Secades JJ; Lozano R; Dávalos A; Castillo J; Lizasoain I
    Neurobiol Dis; 2005 Mar; 18(2):336-45. PubMed ID: 15686962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic potential of GPR119 agonists for type 2 diabetes.
    Ohishi T; Yoshida S
    Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.